EA201590088A1 - Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета - Google Patents
Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабетаInfo
- Publication number
- EA201590088A1 EA201590088A1 EA201590088A EA201590088A EA201590088A1 EA 201590088 A1 EA201590088 A1 EA 201590088A1 EA 201590088 A EA201590088 A EA 201590088A EA 201590088 A EA201590088 A EA 201590088A EA 201590088 A1 EA201590088 A1 EA 201590088A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pancreatic
- diabetes mellitus
- cells
- dependent diabetes
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1329—Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
Свежую ткань поджелудочной железы человека можно использовать в качестве источника клеток для идентификации и отбора популяции нестволовых клеток, которая может стать источником суррогатных клеток поджелудочной железы, которые можно использовать для лечения инсулинозависимого сахарного диабета. Клетки-предшественники указанных суррогатных клеток поджелудочной железы не имеют репрограммирующих генов, интегрированных в их геном, дифференцируются в панкреатическом направлении в соответствии с протоколом, в котором используют только определенные реагенты, и, по существу, не способны к дифференцировке в мезодермальном направлении.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261664259P | 2012-06-26 | 2012-06-26 | |
PCT/US2013/047243 WO2014004341A1 (en) | 2012-06-26 | 2013-06-24 | Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201590088A1 true EA201590088A1 (ru) | 2015-04-30 |
EA033954B1 EA033954B1 (ru) | 2019-12-13 |
Family
ID=48746139
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590088A EA033954B1 (ru) | 2012-06-26 | 2013-06-24 | Неплюрипотентные клетки-предшественники суррогатных клеток поджелудочной железы и способ их получения |
EA201992135A EA201992135A1 (ru) | 2012-06-26 | 2013-06-24 | Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992135A EA201992135A1 (ru) | 2012-06-26 | 2013-06-24 | Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета |
Country Status (16)
Country | Link |
---|---|
US (2) | US9968639B2 (ru) |
EP (2) | EP2864473B1 (ru) |
JP (2) | JP6386453B2 (ru) |
KR (2) | KR102174581B1 (ru) |
CN (2) | CN104640979B (ru) |
AU (2) | AU2013280698B2 (ru) |
BR (1) | BR112014031676A2 (ru) |
CA (1) | CA2876677C (ru) |
DK (1) | DK2864473T3 (ru) |
EA (2) | EA033954B1 (ru) |
ES (1) | ES2745704T3 (ru) |
IL (2) | IL236346B (ru) |
IN (1) | IN2015DN00281A (ru) |
PT (1) | PT2864473T (ru) |
SG (1) | SG11201408717XA (ru) |
WO (1) | WO2014004341A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106467918B (zh) * | 2015-08-18 | 2020-07-31 | 中国科学技术大学先进技术研究院 | 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用 |
CN105434471A (zh) * | 2015-11-26 | 2016-03-30 | 深圳爱生再生医学科技有限公司 | 治疗糖尿病的干细胞制剂及其制备方法 |
CN111836885B (zh) * | 2018-02-09 | 2024-07-09 | 塞拉克西斯股份有限公司 | 用于治疗糖尿病的胰腺细胞及其生成方法 |
CN112888778A (zh) * | 2018-10-15 | 2021-06-01 | Cynity株式会社 | 通过低分子化合物由源自内胚层组织或器官的细胞制备干细胞/祖细胞的方法 |
AU2020403679A1 (en) * | 2019-12-11 | 2022-07-07 | The University Of Tokyo | Induction of proliferous pancreatic islet precursor cell-like cells by transient expression of Mycl and induction of differentiation into insulin-positive cells |
US20220409855A1 (en) | 2021-06-29 | 2022-12-29 | Staffan Holmin | Methods of delivering cells and therapeutic agents to organs and extravascular sites |
WO2023199113A1 (en) | 2022-04-15 | 2023-10-19 | Smartcella Solutions Ab | COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS |
WO2024163938A1 (en) | 2023-02-03 | 2024-08-08 | Seraxis, Inc. | Therapeutic cells and methods relating to the same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861313A (en) * | 1995-06-07 | 1999-01-19 | Ontogeny, Inc. | Method of isolating bile duct progenitor cells |
CA2357677A1 (en) | 1999-01-07 | 2000-07-13 | Incyte Pharmaceuticals, Inc. | Insulin-synthesis genes |
US6815203B1 (en) * | 1999-06-23 | 2004-11-09 | Joslin Diabetes Center, Inc. | Methods of making pancreatic islet cells |
US6866843B2 (en) | 1999-12-06 | 2005-03-15 | Viacell, Inc. | Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell |
US20030082155A1 (en) | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
US6436704B1 (en) * | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
EP1539928A4 (en) | 2002-09-06 | 2006-09-06 | Amcyte Inc | POSIOTIVE PANCREATIC ENDOCRINE PROGENITOR CELLS CD56 IN ADULT HUMAN BEINGS |
JP2007520194A (ja) | 2003-06-20 | 2007-07-26 | ブレイエ・ユニバージテイト・ブリュッセル | 外分泌膵臓細胞から、膵島ベータ−細胞を生成する方法 |
CA2581424A1 (en) * | 2004-03-09 | 2005-09-22 | Gang Xu | Methods for generating insulin-producing cells |
US20060029987A1 (en) | 2004-08-06 | 2006-02-09 | Applera Corporation | Diagnosis of pancreatic cancer by using pancreatic targets |
US7807459B2 (en) | 2005-09-27 | 2010-10-05 | Reneuron, Inc. | EphA4-positive human adult pancreatic endocrine progenitor cells |
US20100137202A1 (en) * | 2006-07-19 | 2010-06-03 | University Of Florida Research Foundation | Compositions for reprogramming a cell and uses therefor |
WO2008112278A2 (en) | 2007-03-12 | 2008-09-18 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
EP2205724B1 (en) * | 2007-11-09 | 2016-04-27 | RNL Bio Co., Ltd. | Method for isolating and culturing adult stem cells derived from human amniotic epithelium |
US8470595B2 (en) | 2008-04-18 | 2013-06-25 | National University Corporation Nagoya University | Mesenchymal stem cell and method for production thereof |
JP2011519574A (ja) * | 2008-05-09 | 2011-07-14 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー | 細胞ベースの治療に関連する材料および方法 |
WO2010022395A2 (en) * | 2008-08-22 | 2010-02-25 | President And Fellows Of Harvard College | Methods of reprogramming cells |
CN102272142A (zh) * | 2008-12-23 | 2011-12-07 | 帷幄生物技术公司 | 非遗传修饰性重编程细胞的组合物和方法 |
WO2011032025A2 (en) * | 2009-09-10 | 2011-03-17 | The Salk Institute For Biological Studies | Adipose-derived induced pluripotent stem cells |
WO2011143299A2 (en) * | 2010-05-12 | 2011-11-17 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
US9394523B2 (en) * | 2010-08-22 | 2016-07-19 | Ramot At Tel-Aviv University Ltd. | Induced pluripotent stem cells derived from human pancreatic beta cells |
MX348537B (es) * | 2010-08-31 | 2017-06-07 | Janssen Biotech Inc | Diferencia de celulas madre pluripotentes. |
WO2012035539A1 (en) * | 2010-09-15 | 2012-03-22 | Ramot At Tel-Aviv University Ltd. | Methods of expanding and redifferentiating islet beta cells |
US20120135015A1 (en) * | 2010-09-28 | 2012-05-31 | Baylor Research Institute | Induction of Pancreatic Stem Cells by Transient Overexpression of Reprogramming Factors and PDX1 Selection |
-
2013
- 2013-06-24 EA EA201590088A patent/EA033954B1/ru not_active IP Right Cessation
- 2013-06-24 KR KR1020197036838A patent/KR102174581B1/ko active IP Right Grant
- 2013-06-24 CN CN201380033028.9A patent/CN104640979B/zh active Active
- 2013-06-24 PT PT13733516T patent/PT2864473T/pt unknown
- 2013-06-24 US US13/925,248 patent/US9968639B2/en active Active
- 2013-06-24 CN CN202110419726.9A patent/CN113265370A/zh active Pending
- 2013-06-24 EA EA201992135A patent/EA201992135A1/ru unknown
- 2013-06-24 BR BR112014031676A patent/BR112014031676A2/pt not_active Application Discontinuation
- 2013-06-24 KR KR1020157000845A patent/KR102058259B1/ko active IP Right Grant
- 2013-06-24 WO PCT/US2013/047243 patent/WO2014004341A1/en active Application Filing
- 2013-06-24 JP JP2015520349A patent/JP6386453B2/ja active Active
- 2013-06-24 DK DK13733516.2T patent/DK2864473T3/da active
- 2013-06-24 EP EP13733516.2A patent/EP2864473B1/en active Active
- 2013-06-24 ES ES13733516T patent/ES2745704T3/es active Active
- 2013-06-24 CA CA2876677A patent/CA2876677C/en active Active
- 2013-06-24 AU AU2013280698A patent/AU2013280698B2/en active Active
- 2013-06-24 EP EP19185702.8A patent/EP3611255A1/en active Pending
- 2013-06-24 SG SG11201408717XA patent/SG11201408717XA/en unknown
-
2014
- 2014-12-18 IL IL236346A patent/IL236346B/en active IP Right Grant
-
2015
- 2015-01-13 IN IN281DEN2015 patent/IN2015DN00281A/en unknown
- 2015-04-22 US US14/693,245 patent/US9474772B2/en active Active
-
2018
- 2018-08-09 JP JP2018149816A patent/JP6856586B2/ja active Active
-
2019
- 2019-03-26 AU AU2019202085A patent/AU2019202085A1/en not_active Abandoned
- 2019-05-28 IL IL266965A patent/IL266965B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590088A1 (ru) | Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета | |
MX2018005332A (es) | Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a. | |
EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
MX2021009672A (es) | Regulacion transcripcional guiada por acido ribonucleico. | |
EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
JP2012140442A5 (ru) | ||
WO2011097181A3 (en) | Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders | |
MX2019007492A (es) | Composiciones de celulas t deficientes del receptor de celulas t. | |
BR112014005355A2 (pt) | células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença | |
EA201491700A1 (ru) | Человеческие антитела к cd27, методы и применение | |
EA201300323A1 (ru) | Материалы и способы улучшения функции желудочно-кишечного тракта | |
EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
WO2014011901A3 (en) | Methods and compositions for delivery of biologics | |
TR201911199T4 (tr) | Hücre büyümesini arttırmak için tedavi. | |
MX2013004061A (es) | Analogos de ciclosporina. | |
MX2019003619A (es) | Formulaciones de bromocriptina. | |
WO2009017655A3 (en) | Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof | |
WO2011163531A3 (en) | Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases | |
CA2862332C (en) | Anti-asic1 antibodies and uses thereof | |
MX366369B (es) | Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo. | |
MX2015008436A (es) | Composiciones para permeabilizar celulas sanguineos fijos y sus usos. | |
MX2013004062A (es) | Analogos de ciclosporina. | |
WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
IN2014MN01493A (ru) | ||
EA201792143A1 (ru) | Лекарственная форма для продленного высвобождения действующих веществ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |